AI Article Synopsis
- Glucagon-like peptide-1 receptor agonists (GLP-1RA) may be linked to a higher risk of acute pancreatitis (AP) in some cases.
- A real-world study found no increased frequency of AP among adults with Type 2 diabetes (T2D) who had a prior history of AP when using GLP-1RAs.
- The study suggests that GLP-1RAs are potentially safe for T2D patients with previous AP issues, but further research is still needed.
Article Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diabres.2024.111806 | DOI Listing |
Publication Analysis
Top Keywords
acute pancreatitis
8
incidence acute
4
pancreatitis glp-1
4
glp-1 receptor
4
receptor agonist
4
agonist therapy
4
therapy individuals
4
individuals history
4
history pancreatitis
4
pancreatitis glucagon-like
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!